Drug Application
Clinical effect of trimebutine maleate combined with Bacillus licheniformis capsulein on irritable bowel syndrome
Zhang Nina, Zhang Aiguo, Chen Yuting, Zhao Pingping, Xu Yana, Xu Zhe
Published 2022-10-10
Cite as Chin J Pract Med, 2022, 49(19): 112-115. DOI: 10.3760/cma.j.cn115689-20220626-02792
Abstract
ObjectiveTo investigate the clinical effect of trimebutine maleate combined with Bacillus licheniformis capsule in the treatment of irritable bowel syndrome (IBS).
MethodsA total of 89 patients with IBS treated in Jincheng People’s Hospital from January 2018 to January 2021 were selected, and they were divided into trimebutine maleate group (30 cases), Bacillus licheniformis capsule group (29 cases) and combined medication group (30 cases) according to the random number table method. The trimebutine maleate group took trimebutine maleate orally, the Bacillus licheniformis capsule group took Bacillus licheniformis capsule orally, and the combined medication group was treated with both of the two medications. Curative effect, blood indicators including neuropeptide Y (NPY), 5-hydroxytryptamine (5-HT) and substance P (SP), inflammatory cytokines including tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and interleukin-8 (IL-6), and complications were compared among the three groups.
ResultsThe total effective rate in the combined medication group (96.67%, 29/30) was higher than those in the trimebutine maleate group (73.33%, 22/30) and Bacillus licheniformis capsule group (68.97%, 20/29), P<0.05. After treatment, the levels of NPY, 5-HT, SP, TNF-α, IL-6 and IL-8 in the three groups were lower than those before treatment (all P<0.05), and these indicators in the combined medication group were lower than those in the trimebutine maleate group and the Bacillus licheniformis capsule group (P<0.05). There was no significant difference in the total incidence of adverse reactions among the trimebutine maleate group (6.67%, 2/30), the Bacillus licheniformis capsule group (6.90%, 2/30) and the combined medication group (3.33%, 1/30), P>0.05.
ConclusionsBoth of trimebutine maleate and Bacillus licheniformis capsule are effective in the treatment of patients with IBS. However, combination of the two can not only achieve better effect than single drug protocols, but also lower the incidence of adverse reactions.
Key words:
Trimebutine maleate; Bacillus licheniformis capsule; Irritable bowel syndrome
Contributor Information
Zhang Nina
Department of Gastroenterology, Jincheng People’s Hospital, Jincheng 048026, China
Zhang Aiguo
Department of Gastroenterology, Jincheng People’s Hospital, Jincheng 048026, China
Chen Yuting
Department of Gastroenterology, Jincheng People’s Hospital, Jincheng 048026, China
Zhao Pingping
Department of Gastroenterology, Jincheng People’s Hospital, Jincheng 048026, China
Xu Yana
Department of Gastroenterology, Jincheng People’s Hospital, Jincheng 048026, China
Xu Zhe
Department of Gastroenterology, Dongguan People’s Hospital, Dongguan 523058, China
